Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
The goal is not to suppress immunity broadly
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
20mg Vial Recommendation for 20mg vial: Add 2ml of BAC water
Experimental data show that BPC-157 promotes VEGFR2 signaling and upregulates endothelial nitric oxide synthase (eNOS) through the SrcCaveolin-1 pathway, resulting in improved vasomotor tone and blood flow restoration
US$ 28.14
US$ 21.38
US$ 29.60
US$ 27.82
US$ 24.21
US$ 23.74
US$ 21.52
US$ 21.92
US$ 29.95
US$ 20.97
US$ 20.35
US$ 25.91
